^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRT17 overexpression

    i
    Other names: KRT17, Keratin 17, Keratin Type I Cytoskeletal 17, Keratin 17 Type I, Cytokeratin-17, CK-17, K17, Keratin-17, PCHC1, PC2, PC
    Entrez ID:
    3872
    Related biomarkers:
    Expression
    2ms
    MicroRNA-485-5p targets keratin17 to regulate pancreatic cancer cell proliferation and invasion via the FAK / SRC / ERK pathway. (PubMed, J Cancer)
    The silenced KRT17 remarkably downregulated the expression of cyclinD1, Cyclin Dependent Kinase 1 (CDK1), CDK2, Phospho-Focal Adhesion Kinase (p-FAK), p-Src, and p-ERK proteins in the PC cells. Generally, an essential signaling cascade of miRNA-485-5p/KRT17/FAK/Src/ERK influences the biological functions of PC cells.
    Journal
    |
    CCND1 (Cyclin D1) • KRT7 (Keratin-7) • CDK2 (Cyclin-dependent kinase 2) • KRT17 (Keratin 17) • CDK1 (Cyclin-dependent kinase 1) • MIR485 (MicroRNA 485)
    |
    CCND1 expression • KRT17 overexpression • KRT7 expression • CDK2 expression
    2ms
    High KRT17 expression in tumour budding indicates immunologically 'hot' tumour budding and predicts good survival in patients with colorectal cancer. (PubMed, Clin Transl Immunology)
    Notably, low KRT17TB can specifically identify those patients with a poor prognosis among colorectal cancer patients with low TB and high T-lymphocyte infiltration. KRT17 can be employed as a new indicator for distinguishing different immunological TBs.
    Journal
    |
    CD8 (cluster of differentiation 8) • KRT17 (Keratin 17)
    |
    KRT17 overexpression • KRT7 expression
    7ms
    Stress keratin 17 (K17) expression as a predictor of response to immune check-point blockade (ICB) treated anal, vulvar, and cervical carcinoma (SITC 2023)
    Among patients receiving pembrolizumab-based therapy (n=21), there were 12 (57...There was no correlation between K17 and individual markers. Conclusions Our findings suggest an inverse trend between K17 expression and clinical outcomes, pending further validation in an expanded patient cohort.
    PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD68 (CD68 Molecule) • KRT17 (Keratin 17)
    |
    KRT17 overexpression
    |
    Keytruda (pembrolizumab)
    10ms
    KRT17 promotes T-lymphocyte infiltration through the YTHDF2-CXCL10 axis in colorectal cancer. (PubMed, Cancer Immunol Res)
    In a cohort of patients with colorectal cancer receiving pembrolizumab, high KRT17 expression was found within the tumors of responders. Collectively, we elucidated a critical role of KRT17 in CRC to prevent immune escape. These findings present new insights into potential therapeutic strategies and effective markers of immunotherapy reactivity against pMMR tumors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • KRT17 (Keratin 17) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    MSI-H/dMMR • KRT17 overexpression • KRT7 expression
    |
    Keytruda (pembrolizumab)